Compare Intuit Inc. (INTU) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Revvity Inc — how do they compare? Intuit Inc. trades at $302.75 (market cap $81.21B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Intuit Inc. is far larger — about 4.8× Revvity Inc's market cap, and Intuit Inc. pays the higher dividend (1.82%). Which is the better fit depends on your goals — on Pluang, investors hold Intuit Inc. for 66 Days and Revvity Inc for 12 Days on average.
| INTU | RVTY | |
|---|---|---|
Market Cap | $81.21B | $16.98B |
Volume | 5,165,806 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $683.39 | $157.36 |
52-Week Low | $255.07 | $82.26 |
Typical Hold Time | 66 Days | 12 Days |
Enterprise Value | $82.43B | $19.30B |
Dividend Yield | 1.82% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $303.88, up 2.23% today, with strong technical momentum as it approaches resistance near $307. The company demonstrates robust fundamentals with revenue growth from $18.83B in 2025 to projected $21.4B in 2026, net margins expanding to 21.29%, and consistent earnings beats in recent quarters. Analyst consensus remains bullish with a $379.68 price target, though recent class action lawsuits create near-term sentiment headwinds.
INTU presents a compelling growth story with strong profitability and market leadership in financial software. The primary investment opportunity lies in continued QuickBooks and TurboTax monetization, while risks include legal overhang from securities litigation and competitive pressures in the fintech space. Current valuation at 18.46 P/E appears reasonable given earnings growth trajectory.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
